Theranostics, Benign Disease, and Service Line Growth

 

Adding a service line as a referral, capital form, and margin decision.

 

Medsolve Dynamics advises oncology programs on service line additions, including theranostics and benign disease, as referral and capital-form decisions rather than equipment purchases.

 

Short field notes, recorded as they came up. Newest first.

 

 

Running the Theranostics Plan at Drug Margin Zero

July 8, 2026 · Listen

The CY 2027 OPPS proposed rule puts the 340B drug spread underneath hospital theranostics programs on the table. Two drugs carry the category, Pluvicto and Lutathera, and for many programs the spread is what made the line lucrative. This episode covers the discipline: nobody tears up a program on a proposed rule, and nobody signs capital before checking whether the plan still works if the rule sticks. Three drug prices to test before the FY28 budget locks, and what a theranostics business plan has to stand on when the drug margin goes to zero.

 

Why a Radioligand No-Show Costs Differently Than a Missed Fraction.

June 11, 2026 · Listen

Lutetium-177 has a half-life of about 6.6 days, so a radioligand therapy no-show is a paid dose decaying in your department. The dose economics behind theranostics scheduling and isotope supply.

 

Why a Theranostics No-Show Hurts Differently Than an IMRT One

June 3, 2026 · Listen

In radiation oncology, a curative no-show is a slot you backfill. In theranostics, the Lu-177 dose is a fixed amount with about a five-day shelf life, scheduled for one patient, and it cannot wait for a better day. Here is how scheduling discipline, authorized user coverage, and capture mechanics determine whether a theranostics service line holds its margin, and the two operating costs the vendor proforma leaves out.

 

A Guideline Says It Is Appropriate. The Next Question Is Whether Your Program Can Deliver It.

June 2, 2026 · Listen

A society guideline on low-dose radiation for osteoarthritis makes benign disease a real service-line conversation in radiation oncology. Clinical appropriateness and program readiness are different questions. Here is the operational and financial read: the referral pathway, the payer coverage and prior-authorization pathway, and using open LINAC capacity for incremental benign volume without affecting the curative schedule.

 

Adding Benign Disease Is A Referral Decision, Not An Equipment Decision

May 11, 2026 · Listen

Benign disease radiation uses LINAC capacity that is already paid for in most programs. The growth question is referral pathway, not capital. From 20 years of watching programs add and grow service lines.

 

Theranostics Capital Decisions Are Build-Or-Partner Decisions, Not Product Decisions

May 11, 2026 · Listen

From 20 years on the vendor side and now on the program side, the capital form decision that gets skipped on most theranostics service-line additions. Build or partner sets the next decade. With reference to Kenneth Brooks and Christine Stone's published build case study at Wellstar Health System.

 

The importance of ownership and preparation in the successful launch of new service lines.

March 17, 2026 · Listen

The challenges of operationalizing clinical plans and the impact of supply chain disruptions on service lines. The importance of ownership and preparation in the successful launch of new initiatives.

• Operational challenges impact service lines.

• Preparation and ownership are crucial for successful launches.

 

Benign disease as a margin stabilizer.

March 17, 2026 · Listen

The conversation discusses the positioning of benign disease as a stabilizer and the impact of referral behavior on machine utilization.

• Benign disease as a stabilizer.

• Referral behavior impacts machine utilization.

 

Theranostics in radiation oncology requires deliberate design.

March 17, 2026 · Listen

Theranostics in radiation oncology requires a deliberate design of operational infrastructure to ensure ownership, growth, and clinical opportunity. The alignment of theranostics with radiation oncology impacts scheduling, flow, waste protocols, and coordination across departments.

• Operational infrastructure is crucial for the success of theranostics in radiation oncology.

• Theranostics requires deliberate design and coordination across departments.

 

More field notes: Program operations · LINAC service contracts · all seven topics